HALO Volume Alert - HALO 8.72 Halozyme Therapeutics $HALO Hit a high of 8.83 Currently 11:15 Last price 8.72 -0.60 -6.44% With a day low of 8.30 and a current volume of 1,475,236.
HALO Halozyme Therapeutics Recent Headline News
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 8.92 (-0.40)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 8.92 (-0.40)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 8.92 (-0.40)
Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 8.92 (-0.40)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:36PM CST
DTSI: 32.50 (+1.79), W: 23.73 (-4.37), HALO: 8.92 (-0.40), MODN: 10.50 (+0.40), CALL: 8.63 (-1.86), LLNW: 2.70 (+0.20), KRG: 26.99 (+0.05), VSLR: 11.28 (-3.46), CMLS: 3.23 (-0.06), SSE: 11.88 (-0.23)
Halozyme Therapeutics misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:21PM CST
HALO: 8.92 (-0.40)
Halozyme Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million, or $0.16 per share. This compares to revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share, for the third quarter of 2013.
HALO: 8.92 (-0.40)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 3.08 (-0.17), WWD: 48.64 (-3.17), LLNW: 2.70 (+0.20), FXEN: 2.71 (-0.14), RMTI: 11.09 (+0.19), CZR: 10.98 (-0.56), EGY: 7.13 (+0.14), ICUI: 81.36 (+9.55), ICEL: 7.52 (-0.18), SAAS: 9.01 (+0.04), DMD: 5.93 (-1.20), NPSP: 29.26 (+2.35), SCLN: 8.20 (+0.10), ATHX: 1.48 (-0.06), CMLS: 3.23 (-0.06), TC: 2.14 (+0.18), ATW: 35.96 (-1.80), CLUB: 6.12 (-0.65), RAX: 42.27 (+4.95), PTLA: 27.25 (-0.40), IPAR: 28.84 (-0.38), ATLS: 37.24 (+0.37), AMBC: 24.53 (+1.16), CUI: 8.06 (-0.36), PDLI: 8.11 (+0.18), OMER: 19.00 (+1.51), PRAA: 61.28 (-2.57), CARA: 8.60 (-0.15), HALO: 8.92 (-0.40), MODN: 10.50 (+0.40), CALL: 8.63 (-1.86), ASEI: 47.49 (-8.60), HGR: 20.74 (+0.15), ERII: 4.54 (-0.44)
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 8.92 (-0.40)
Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 8.92 (-0.40)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.28 (+0.17), ACAD: 27.37 (-0.84), HALO: 8.92 (-0.40), ISIS: 51.16 (+3.93), NSPH: 0.42 (unch)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 8.92 (-0.40), NLNK: 32.07 (-2.33), ILMN: 188.04 (-0.23), EXAS: 22.46 (-0.14)
Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 4:54PM CDT
Vertex Pharmaceuticals Inc.'s (VRTX) Kaydeco got favorable vote from PADAC for the treatment of 6 year old and above cystic fibrosis patients with R117H mutation.
MDVN: 107.31 (-1.64), VRTX: 117.65 (+0.71), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 12:10PM CDT
Biogen (BIIB) raised its earnings guidance for 2014 once again.
MDVN: 107.31 (-1.64), BIIB: 323.95 (-3.92), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 107.31 (-1.64), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 107.31 (-1.64), OREX: 5.04 (-0.09), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Illumina (ILMN) Looks Strong: Stock Gains 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 7:44AM CDT
Illumina (ILMN) was a big mover last session, as the company saw its shares jump over 9% on the day
MACK: 8.48 (-0.22), MDVN: 107.33 (-1.62), HALO: 8.92 (-0.40), ILMN: 188.04 (-0.23)
NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 107.34 (-1.61), HALO: 8.92 (-0.40), NLNK: 32.07 (-2.33)
Illumina (ILMN) Tops Q3 Earnings, Revenues; Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:40AM CDT
Illumina Inc.(ILMN) reported adjusted earnings of 77 cents per share in the third quarter of 2014, beating the Zacks Consensus Estimate by 37.5%.
MACK: 8.48 (-0.22), MDVN: 107.34 (-1.61), HALO: 8.92 (-0.40), ILMN: 188.04 (-0.23)
Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:39AM CDT
Vital Therapies, Inc. (VTL) was a big mover last session, as its shares rose almost 8% on the day.
MACK: 8.48 (-0.22), HALO: 8.92 (-0.40), VTL: 16.96 (-1.17), ILMN: 188.04 (-0.23)
HALO Halozyme Therapeutics Recent Headline News
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 8.92 (-0.40)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 8.92 (-0.40)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 8.92 (-0.40)
Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 8.92 (-0.40)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:36PM CST
DTSI: 32.50 (+1.79), W: 23.73 (-4.37), HALO: 8.92 (-0.40), MODN: 10.50 (+0.40), CALL: 8.63 (-1.86), LLNW: 2.70 (+0.20), KRG: 26.99 (+0.05), VSLR: 11.28 (-3.46), CMLS: 3.23 (-0.06), SSE: 11.88 (-0.23)
Halozyme Therapeutics misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:21PM CST
HALO: 8.92 (-0.40)
Halozyme Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million, or $0.16 per share. This compares to revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share, for the third quarter of 2013.
HALO: 8.92 (-0.40)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 3.08 (-0.17), WWD: 48.64 (-3.17), LLNW: 2.70 (+0.20), FXEN: 2.71 (-0.14), RMTI: 11.09 (+0.19), CZR: 10.98 (-0.56), EGY: 7.13 (+0.14), ICUI: 81.36 (+9.55), ICEL: 7.52 (-0.18), SAAS: 9.01 (+0.04), DMD: 5.93 (-1.20), NPSP: 29.26 (+2.35), SCLN: 8.20 (+0.10), ATHX: 1.48 (-0.06), CMLS: 3.23 (-0.06), TC: 2.14 (+0.18), ATW: 35.96 (-1.80), CLUB: 6.12 (-0.65), RAX: 42.27 (+4.95), PTLA: 27.25 (-0.40), IPAR: 28.84 (-0.38), ATLS: 37.24 (+0.37), AMBC: 24.53 (+1.16), CUI: 8.06 (-0.36), PDLI: 8.11 (+0.18), OMER: 19.00 (+1.51), PRAA: 61.28 (-2.57), CARA: 8.60 (-0.15), HALO: 8.92 (-0.40), MODN: 10.50 (+0.40), CALL: 8.63 (-1.86), ASEI: 47.49 (-8.60), HGR: 20.74 (+0.15), ERII: 4.54 (-0.44)
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 8.92 (-0.40)
Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 8.92 (-0.40)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.28 (+0.17), ACAD: 27.37 (-0.84), HALO: 8.92 (-0.40), ISIS: 51.16 (+3.93), NSPH: 0.42 (unch)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 8.92 (-0.40), NLNK: 32.07 (-2.33), ILMN: 188.04 (-0.23), EXAS: 22.46 (-0.14)
Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 4:54PM CDT
Vertex Pharmaceuticals Inc.'s (VRTX) Kaydeco got favorable vote from PADAC for the treatment of 6 year old and above cystic fibrosis patients with R117H mutation.
MDVN: 107.31 (-1.64), VRTX: 117.65 (+0.71), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 12:10PM CDT
Biogen (BIIB) raised its earnings guidance for 2014 once again.
MDVN: 107.31 (-1.64), BIIB: 323.95 (-3.92), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 107.31 (-1.64), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 107.31 (-1.64), OREX: 5.04 (-0.09), HALO: 8.92 (-0.40), LGND: 57.10 (+1.42)
Illumina (ILMN) Looks Strong: Stock Gains 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 7:44AM CDT
Illumina (ILMN) was a big mover last session, as the company saw its shares jump over 9% on the day
MACK: 8.48 (-0.22), MDVN: 107.33 (-1.62), HALO: 8.92 (-0.40), ILMN: 188.04 (-0.23)
NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 107.34 (-1.61), HALO: 8.92 (-0.40), NLNK: 32.07 (-2.33)
Illumina (ILMN) Tops Q3 Earnings, Revenues; Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:40AM CDT
Illumina Inc.(ILMN) reported adjusted earnings of 77 cents per share in the third quarter of 2014, beating the Zacks Consensus Estimate by 37.5%.
MACK: 8.48 (-0.22), MDVN: 107.34 (-1.61), HALO: 8.92 (-0.40), ILMN: 188.04 (-0.23)
Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:39AM CDT
Vital Therapies, Inc. (VTL) was a big mover last session, as its shares rose almost 8% on the day.
MACK: 8.48 (-0.22), HALO: 8.92 (-0.40), VTL: 16.96 (-1.17), ILMN: 188.04 (-0.23)
